<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366208</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20046-2</org_study_id>
    <nct_id>NCT02366208</nct_id>
  </id_info>
  <brief_title>Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B</brief_title>
  <acronym>PEG-Tα1</acronym>
  <official_title>Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1
      (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from
      Hansoh Pharmaceutical of China, in combination with adefovir in HBeAg-positive patients with
      chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 116 HBeAg-positive patients were recruited from 12 hospitals in China, and
      randomized to two groups. The combination group (n= 57) received PEG-Tα1 (1.6 mg/ml, once a
      week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 24 weeks. The
      control group (n = 59) received placebo and adefovir. Both groups received adefovir
      continuously for additional 24 weeks. The primary endpoint was the loss of HBeAg at 48 weeks.
      The secondary endpoints included 1) loss of hepatitis B virus ( HBV) DNA, 2) HBeAg
      seroconversion and 3) alanine aminotransferase (ALT) normalization etc. at week 4, 12, 24, 36
      and 48. The number of CD4＋and CD8＋T cells was also determined during 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>loss of HBeAg</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>loss of HBV DNA</measure>
    <time_frame>week 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase normalization</measure>
    <time_frame>week 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>PEG-Tα1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match PEG-Tα1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Tα1</intervention_name>
    <description>1.6 mg/ml, once a week, taken subcutaneously</description>
    <arm_group_label>PEG-Tα1</arm_group_label>
    <other_name>Polyethylene Glycol Thymosin alpha1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match PEG-Tα1</intervention_name>
    <description>1ml, once a week, taken subcutaneously</description>
    <arm_group_label>Placebo to match PEG-Tα1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>10 mg, once daily, taken orally for 48 weeks</description>
    <arm_group_label>PEG-Tα1</arm_group_label>
    <arm_group_label>Placebo to match PEG-Tα1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B for more than 6 months

          -  ALT ＞ 2 × Upper Limit Normal (ULN)

          -  Serum bilirubin ＜ 2 × ULN.

          -  Positive HBeAg and HBV-DNA between 1.00E＋05 IU/ml and 9.99E＋09 IU/ml.

          -  Informed Consent Form (ICF) signed.

        Exclusion Criteria:

          -  Hepatitis A,C,D,E or HIV infection.

          -  Autoimmune hepatitis.

          -  Hepatic cirrhosis.

          -  Serum creatinine ＞ 1.5 × ULN or Ccr ＜ 50 ml/min, Haemoglobin ＜ 110g/L (male) or ＜
             100g/L (female), Platelet＜ 80 E＋09/L, Serum albumin ≤ 32g/L, or Serum albumin/globulin
             (A/G) ≤0.9, Neutrophile granulocyte ＜ 1.0 E＋09/L, Prothrombin time＞ULN＋3 seconds,
             Cholinesterase＜2500U/L.

          -  Hepatitic carcinoma or Alpha Fetal Protein (AFP) ＞ 100ng/ml

          -  Patients with other severe diseases combined, which could affect the therapy.

          -  Patients accepted other clinical trial within 6 months before the first administrated.

          -  Patients accepted immunomodulating or anti-viral treatment within 6 months before the
             trial.

          -  Patients with autoimmune disease.

          -  Thymosin allergy.

          -  Pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>302 Military Hoapital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>81 Military Hospital of China</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyethylene Glycol Thymosin alpha1</keyword>
  <keyword>Adefovir</keyword>
  <keyword>Hepatitis B e Antigens positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

